ARS Pharmaceuticals, Inc. Accumulated Other Comprehensive Income
ARS Pharmaceuticals, Inc. (SPRY) had Accumulated Other Comprehensive Income of -$140.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-13
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$140.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$96.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $125.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$7.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$140.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$96.00K 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $125.00K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$7.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | -$46.00K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $72.00K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $220.00K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $339.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$145.00K 10-Q · filed 2024-08-06 | |
| 2024-03-31 | -$124.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $49.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$161.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$180.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $68.00K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $407.00K 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$1.62M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | -$1.55M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$1.25M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 | -$326.00K 10-K · filed 2022-03-31 |
| 2021-09-30 | -$34.00K 10-Q · filed 2021-11-10 | |
| 2020-12-31 | $0.00 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |